Alto Neuroscience Inc. shares reached an all-time intraday high of $35.42 on Monday, extending a rally that has delivered a 793.91% gain over the past 12 months and a 92.6% increase year-to-date.
The biotechnology company’s market capitalization has expanded to $1.38 billion, reflecting strong investor interest in its neuroscience-focused pipeline. Trading volume remained elevated as the stock approached the $35 level, with technical indicators suggesting overbought conditions.
The rally follows the publication of an independent clinical trial in Nature Medicine, which demonstrated that the dopamine agonist pramipexole significantly reduced anhedonia in patients with mood disorders. The study, conducted by Lund University, provided clinical validation for Alto’s drug development approach, reinforcing confidence in its pipeline candidates.
Alto also announced the pricing of a $100 million stock offering at $26.48 per share, expected to close shortly. The equity raise is intended to fund ongoing research and development initiatives, including the ALTO-207 development plan focused on treatment-resistant depression.
Analysts at H.C. Wainwright upgraded their price target for Alto Neuroscience to $55 from a prior level, maintaining a Buy rating. The upgrade cited the company’s progress in advancing its clinical programs and the positive implications of the Lund University study for its pipeline.
In a separate corporate development, Alto appointed Andrew Miller, Ph.D., to its Board of Directors. Miller brings neuroscience expertise from his prior role at Karuna Therapeutics, where he contributed to the development of COBENFY, a treatment for schizophrenia.
